The journal Nature Medicine have reported that a number of ocular researchers have raised criticisms of a diabetic macular oedema (DME) clinical trial for using… Read More »Potential for off-label use of Lucentis following DRCR clinical results
A double blind Phase III trial in 691 patients has reported that 0.5mg Lucentis plus prompt or deferred laser therapy had a significant improvement in… Read More »Lucentis (ranibizumab) plus laser treatment for DME raises bar for new therapies
Alimera Sciences Inc (NASDAQ:ALIM), headquartered in Georgia, Atlanta have raised $72.1 million through the sale of 6.6 million shares. The specialist ophthalmics company possesses a… Read More »Diabetic macular edema company raises $72 million on NASDAQ
Topcon Medical Systems Inc. (Paramus, New Jersey) have launched a dedicated iPhone application providing a mobile version of the “EyeRoute Image Management” software. The new… Read More »First iPhone application for ophthalmic image management reaches market
A study comparing the use of bevacizumab (marketed as Avastin) and ranibizumab (marketed as Lucentis) has shown that the two “wet” AMD treatments are equally… Read More »US medical insurance firm shows no difference between Avastin and Lucentis treatments
Novartis has proposed a full purchase of Alcon, Inc (ALC:NYSE) for a reported $39.3 billion bringing the total cash price of its Alcon acquisition to… Read More »Novartis announces full takeover plans of Alcon
Potentia Pharmaceuticals, a speciality biotechnology company focused on treatments for AMD, have announced a licensing and share purchase option agreement with Alcon, Inc (ACL:NYSE). The… Read More »Potentia Pharmaceuticals licenses complement pathway inhibitor for macular degeneration
Researchers based at Duke University Medical Centre, North Carolina have developed a new technology using spectral domain optical coherence tomography (SD-OCT) to produce a three-dimensional… Read More »New handheld imaging device finds early signs of retinopathy in premature infants
Gene Signal [www.genesignal.com] based in Lausanne, Switzerland, have reported interim results of a randomized Phase II clinical study on their lead drug candidate, GS-101. The… Read More »Gene Signal’s GS-101 results show safe and effective inhibition of blood vessel growth
SurModics of Minnesota announced the completion of a License and Development Agreement with Roche / Genentech Inc for the use of SurModics’ proprietary microparticulate drug… Read More »Roche / Genentech sign licensing and development deal to access drug delivery formulation for Lucent